KR102575990B1 - Gsk-3 억제제 - Google Patents

Gsk-3 억제제 Download PDF

Info

Publication number
KR102575990B1
KR102575990B1 KR1020197018285A KR20197018285A KR102575990B1 KR 102575990 B1 KR102575990 B1 KR 102575990B1 KR 1020197018285 A KR1020197018285 A KR 1020197018285A KR 20197018285 A KR20197018285 A KR 20197018285A KR 102575990 B1 KR102575990 B1 KR 102575990B1
Authority
KR
South Korea
Prior art keywords
pyrimidine
esi
yield
nmr
heated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197018285A
Other languages
English (en)
Korean (ko)
Other versions
KR20190085114A (ko
Inventor
리처드 에이. 하츠
비제이 티. 아후자
구앙린 뤄
링 첸
프라산나 시바프라카삼
진 엠. 두보우치크
스와니 이. 자쿠틴-포르테
존 이. 마코르
Original Assignee
브리스톨-마이어스 스큅 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 브리스톨-마이어스 스큅 컴퍼니 filed Critical 브리스톨-마이어스 스큅 컴퍼니
Publication of KR20190085114A publication Critical patent/KR20190085114A/ko
Application granted granted Critical
Publication of KR102575990B1 publication Critical patent/KR102575990B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR1020197018285A 2016-11-28 2017-11-27 Gsk-3 억제제 Active KR102575990B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662426631P 2016-11-28 2016-11-28
US62/426,631 2016-11-28
PCT/US2017/063231 WO2018098412A1 (en) 2016-11-28 2017-11-27 Gsk-3 inhibitors

Publications (2)

Publication Number Publication Date
KR20190085114A KR20190085114A (ko) 2019-07-17
KR102575990B1 true KR102575990B1 (ko) 2023-09-08

Family

ID=60655130

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197018285A Active KR102575990B1 (ko) 2016-11-28 2017-11-27 Gsk-3 억제제

Country Status (8)

Country Link
US (1) US10752609B2 (cg-RX-API-DMAC10.html)
EP (1) EP3544613B1 (cg-RX-API-DMAC10.html)
JP (1) JP7114591B2 (cg-RX-API-DMAC10.html)
KR (1) KR102575990B1 (cg-RX-API-DMAC10.html)
CN (1) CN110545817B (cg-RX-API-DMAC10.html)
ES (1) ES2878078T3 (cg-RX-API-DMAC10.html)
MA (1) MA46889A (cg-RX-API-DMAC10.html)
WO (1) WO2018098412A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110198934B (zh) * 2016-11-28 2022-07-22 百时美施贵宝公司 作为gsk-3抑制剂的嘧啶甲酰胺
MA54550A (fr) 2018-12-20 2022-03-30 Amgen Inc Inhibiteurs de kif18a
AU2019401495B2 (en) 2018-12-20 2025-06-26 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
AU2019404576B2 (en) * 2018-12-20 2025-07-17 Amgen Inc. Heteroaryl amides useful as KIF18A inhibitors
AU2020325115B2 (en) 2019-08-02 2026-03-12 Amgen Inc. Pyridine derivatives as KIF18A inhibitors
JP7699100B2 (ja) 2019-08-02 2025-06-26 アムジエン・インコーポレーテツド Ｋｉｆ１８ａ阻害剤
CN116178281B (zh) * 2023-04-27 2023-07-21 中国药科大学 一种双功能免疫抑制剂及其制备方法和应用
CN121666382A (zh) * 2023-05-10 2026-03-13 缆图药品公司 GSK3α抑制剂和其使用方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069594A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Gsk-3 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102438D0 (sv) * 2001-07-05 2001-07-05 Astrazeneca Ab New compounds
BRPI0814441A2 (pt) * 2007-07-19 2015-07-14 Schering Corp Compostos de amida heterocíclica como inibidores de proteína cinase
WO2012024179A1 (en) * 2010-08-18 2012-02-23 Merck Sharp & Dohme Corp. Substituted amide derivatives as dgat-1 inhibitors
JP2017500287A (ja) * 2013-11-06 2017-01-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｇｓｋ−３阻害剤として有用な置換ピリジン誘導体
WO2016144792A1 (en) * 2015-03-06 2016-09-15 Alpharmagen, Llc Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
CN110198934B (zh) * 2016-11-28 2022-07-22 百时美施贵宝公司 作为gsk-3抑制剂的嘧啶甲酰胺

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069594A1 (en) 2013-11-06 2015-05-14 Bristol-Myers Squibb Company Gsk-3 inhibitors

Also Published As

Publication number Publication date
MA46889A (fr) 2019-10-02
US20190315714A1 (en) 2019-10-17
US10752609B2 (en) 2020-08-25
ES2878078T3 (es) 2021-11-18
KR20190085114A (ko) 2019-07-17
JP7114591B2 (ja) 2022-08-08
JP2019535788A (ja) 2019-12-12
EP3544613A1 (en) 2019-10-02
CN110545817A (zh) 2019-12-06
EP3544613B1 (en) 2021-06-09
CN110545817B (zh) 2022-11-15
WO2018098412A1 (en) 2018-05-31

Similar Documents

Publication Publication Date Title
JP7114591B2 (ja) Ｇｓｋ－３阻害剤
EP2459535B1 (en) Pyridine and pyrazine derivatives as protein kinase modulators
RU2362771C1 (ru) Новое производное пиридина и производное пиримидина (3)
KR102339227B1 (ko) Gsk-3 억제제
JP6377081B2 (ja) 新規ピリミジン化合物
TW202016094A (zh) 週期素依賴性激酶抑制劑
KR102292433B1 (ko) Gsk-3 억제제로서 유용한 치환된 피리딘 유도체
EA039808B1 (ru) Аминотриазолопиридины в качестве ингибиторов киназ
EP2668162A1 (en) Substituted bi-heteroaryl compounds as cdk9 inhibitors and their uses
MX2014008647A (es) Compuesto de pirazin-carboxamida.
JP2019504854A (ja) Ｎｒ２ｂ選択的ｎｍｄａ調節因子としての置換１，２，３−トリアゾール
KR20130062951A (ko) 키누레닌 생성 억제 작용을 갖는 함질소 복소환 화합물
WO2012101065A2 (en) Pyrimidine biaryl amine compounds and their uses
WO2012101066A1 (en) Pyridine biaryl amine compounds and their uses
KR20240047371A (ko) Cd38 조절제 및 이의 사용 방법
CA3196676A1 (en) Pyrimidine compounds, compositions, and medicinal applications thereof
JP6977038B2 (ja) Ｇｓｋ−３阻害剤

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190625

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201028

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230102

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230603

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230904

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230905

End annual number: 3

Start annual number: 1

PG1601 Publication of registration